image
Healthcare - Biotechnology - NASDAQ - US
$ 0.2219
-12.9 %
$ 1.67 M
Market Cap
-0.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PTIX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.222 USD, Protagenic Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PTIX stock under the base case scenario is HIDDEN Compared to the current market price of 0.222 USD, Protagenic Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one PTIX stock under the best case scenario is HIDDEN Compared to the current market price of 0.222 USD, Protagenic Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PTIX

image
$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2$0.1$0.1Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-5.7 M OPERATING INCOME
-25.93%
-5.53 M NET INCOME
-10.50%
-4.22 M OPERATING CASH FLOW
-13.84%
2.8 M INVESTING CASH FLOW
-41.31%
1.96 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-1.64 M OPERATING INCOME
-152.00%
-1.55 M NET INCOME
-142.47%
-820 K OPERATING CASH FLOW
-341.55%
0 INVESTING CASH FLOW
0.00%
1.6 M FINANCING CASH FLOW
405.45%
Balance Sheet Protagenic Therapeutics, Inc.
image
Current Assets 1.88 M
Cash & Short-Term Investments 1.84 M
Receivables 0
Other Current Assets 44.4 K
Non-Current Assets 73 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 73 K
94.00 %3.73 %Total Assets$2.0m
Current Liabilities 943 K
Accounts Payable 103 K
Short-Term Debt 0
Other Current Liabilities 840 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
10.92 %89.08 %Total Liabilities$942.8k
EFFICIENCY
Earnings Waterfall Protagenic Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 5.7 M
Operating Income -5.7 M
Other Expenses -176 K
Net Income -5.53 M
00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)(6m)(6m)000(6m)(6m)176k(6m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-545.36% ROE
-545.36%
-282.49% ROA
-282.49%
-562.69% ROIC
-562.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Protagenic Therapeutics, Inc.
image
00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(3m)(3m)(3m)(3m)(4m)(4m)(4m)(4m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -5.53 M
Depreciation & Amortization 50.3 K
Capital Expenditures 0
Stock-Based Compensation 923 K
Change in Working Capital 468 K
Others 335 K
Free Cash Flow -4.22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Protagenic Therapeutics, Inc.
image
PTIX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Protagenic Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today that on November 4, 2024 it closed its previously announced private placement pursuant to a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock, series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date, and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants was $0.64 ($0.89 in the case of insiders). accesswire.com - 5 months ago
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 shares of common stock (or pre-funded warrants in lieu of shares of common stock), series A common stock purchase warrants to purchase an aggregate of 1,948,295 shares of common stock, with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date (as defined in the Purchase Agreement) for a term of eighteen (18) months from the Stockholder Approval Date (as defined in the Purchase Agreement), and series B common stock purchase warrants to purchase an aggregate of 1,948,295 shares of Common Stock with an exercise price of $0.64 per share, which are exercisable on the trading day immediately following the Stockholder Approval Date for a term of five (5) years from the Stockholder Approval Date. The purchase price of each share of common stock and associated common stock purchase warrants will be $0.64 ($0.89 in the case of insiders). accesswire.com - 6 months ago
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1 trial involving PT00114, its synthetic stress-regulating peptide, for treating neuropsychiatric disorders. This marks a significant milestone with the enrollment of 30 subjects across five cohorts, receiving doses up to 1,000 micrograms. accesswire.com - 1 year ago
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston. Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions. accesswire.com - 1 year ago
Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript seekingalpha.com - 1 year ago
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portion Plans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next month NEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. "In 2023, Protagenic Therapeutics achieved a significant milestone as we began enrolling patients for our neuropeptide drug candidate, PT00114," said Dr. Garo Armen, Executive Chairman. accesswire.com - 1 year ago
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached another milestone by completing three out of five cohorts of healthy volunteers with PT00114, its synthetic version of the stress-regulating peptide TCAP, in a SAD Phase 1 clinical trial. accesswire.com - 1 year ago
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Company plans to hold its first investor earnings call to discuss the results contained in its FY 2023 Form 10K, which it plans to file that day, and its outlook for FY 2024. The Company plans to hold its earnings call, open to the public, at 4:30 pm ET on Monday, April 1st, to discuss the results of its Q4 and FY 2023, which it plans to publish in its Form 10K to be filed with the SEC that day. accesswire.com - 1 year ago
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing. accesswire.com - 1 year ago
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders Company Anticipates Reporting Complete Phase I Single Dose Results in April NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced a step forward in its mission to address stress-related neuro-psychiatric disorders. The company has completed the first dose escalation step in the Phase I safety clinical trial for PT00114, its pioneering brain peptide compound. accesswire.com - 1 year ago
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th. Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023. accesswire.com - 1 year ago
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114 A potential major step toward treating stress-related neuro-psychiatric disorders NEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneering biopharmaceutical company, has announced the commencement of its Phase I/IIa clinical trial for PT00114, its leading drug candidate. Key Highlights: Clinical Trial Focus: The trial aims to evaluate the therapeutic potential of PT00114, a synthetic version of the naturally occurring brain peptide TCAP, in treating an array of neuro-psychiatric conditions, including depression, anxiety, and PTSD. accesswire.com - 1 year ago
8. Profile Summary

Protagenic Therapeutics, Inc. PTIX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.67 M
Dividend Yield 0.00%
Description Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Contact 149 Fifth Avenue, New York, NY, 10010 https://www.protagenic.com
IPO Date April 27, 2021
Employees 1
Officers Dr. Alexander Kenneth Arrow C.F.A., M.D. Chief Financial Officer & Secretary Dr. Andrew Slee Ph.D. Chief Operating Officer Dr. Garo H. Armen Ph.D. Co-Founder & Executive Chairman of the Board Dr. Robert Benjamin Stein M.D., Ph.D. Chief Medical Officer & Director